Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above: primary endpoint…
- Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01147068).
- Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine: primary endpoint results, effect…
- Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age: primary endpoint results, effect estimate…
- Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea: primary endpoint results, effect estimate with confidence…
- Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Safety and Immunogenicity Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years: primary endpoint results, effect estimate with…
- Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04074928).
- Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Immunogenicity Study of Traveler’s Diarrhea Vaccine Patch: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01067781).
- Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever: Complete Statistical AnalysisIndependent statistical analysis of Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Performance Assessment of a First Four Arms on Demand Open Robotic Solution for Assisted PN, RN and RP: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Assessment of a First Four Arms on Demand Open Robotic Solution for Assisted PN, RN and RP: primary endpoint results, effect estimate with confidence interval,…
- Safety and Performance of HiRes Ultra/Ultra 3D Cl Mid-Scala Electrodes in Adults With Severe-to-profound Hearing Loss: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of HiRes Ultra/Ultra 3D Cl Mid-Scala Electrodes in Adults With Severe-to-profound Hearing Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG): Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Safety and Performance Study of the Harpoon Mitral Valve Repair System: Complete Statistical AnalysisIndependent statistical analysis of Safety and Performance Study of the Harpoon Mitral Valve Repair System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma: primary endpoint results, effect…
- Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016): primary endpoint results, effect estimate with…
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00845650).
- Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Safety and Pharmacology Study of VP 20629 in Adults With Friedreich’s Ataxia: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease: Complete Statistical AnalysisIndependent statistical analysis of Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: Complete Statistical AnalysisIndependent statistical analysis of Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn: Complete Statistical AnalysisIndependent statistical analysis of Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV Vaccine (PoliorixTM) in Toddlers: Complete Statistical AnalysisIndependent statistical analysis of Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients: Complete Statistical AnalysisIndependent statistical analysis of Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Safety and Tolerability of Artificial Tears in Dry Eye Subjects: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Artificial Tears in Dry Eye Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00932477).
- Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055): Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer: Complete Statistical AnalysisIndependent statistical analysis of Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…